Study protocol for a phase 1/2, single-centre, double-blind, double-dummy, randomized, active-controlled, age de-escalation trial to assess the safety, tolerability and immunogenicity of a measles and rubella vaccine delivered by a microneedle patch in healthy adults (18 to 40 years), measles and rubella vaccine-primed toddlers (15 to 18 months) and measles and rubella vaccine-na ïve infants (9 to 10 months) in The Gambia [Measles and Rubella Vaccine Microneedle Patch Phase 1/2 Age De-escalation Trial]
DiscussionThis trial will provide the first clinical data on the use of a MNP to deliver the MRV and the first data on the use of MNPs in a paediatric population. It will guide future product development decisions for what may be a key technology for future measles and rubella elimination.Trial registrationPan-African Clinical Trials Registry202008836432905.ClinicalTrials.govNCT04394689 (Source: Trials)
Source: Trials - September 14, 2022 Category: Research Source Type: clinical trials
The Immunogenicity and Safety of the Vaccination of Human Papillomavirus Vaccine and Measles-Mumps-Rubella Vaccine
Conditions: Human Papilloma Virus Infection Type 16; Human Papilloma Virus Infection Type 18; Measles; Rubella; Mumps Interventions: Biological: HPV+MMR（0d），HPV（6m）; Biological: HPV（0d），HPV（6m），MMR（7m）; Biological: MMR（0d），HPV（1m），HPV（7m） Sponsor: Zhejiang Provincial Center for Disease Control and Prevention Active, not recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - March 15, 2022 Category: Research Source Type: clinical trials
Clinical Trial of Measles, Mumps and Rubella Combined Vaccine, Live
Condition: Immunogenicity, Vaccine Intervention: Biological: Measles, Mumps and Rubella Combined Vaccine, Live Sponsor: Shanghai Institute Of Biological Products Not yet recruiting (Source: ClinicalTrials.gov)
Source: ClinicalTrials.gov - December 17, 2021 Category: Research Source Type: clinical trials
